Abstract

CLC Number:

R542.22

[1]	DENG Shao-xiong, GUO Nan-ou, ZHENG-Yuan, HUANG Wen-sen. Effect and clinical significance of tirofiban on serum matrix metalloproteinase 9 after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction and diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(7): 807-811.
[2]	Xu Zhimin, Wang Lei, Hu Dayi, Zhai Liang, Wu Yafeng, Liu Xianhui, Liu Jianzhang. Relationship between cardiac diastolic function and the efficacy of thrombolytic therapy on acute myocardial infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 1997, 2(1): 41-42.
[3]	CHEN Li-Xin, WANG Xin-Fang1, XIE Ming-Xing1, ZHU Xiang-Ming2, WU Ying. Evaluation of release kinetics of serum creatine kinase isoenzyme MB and cardiac troponin I during no-reflow phenomenon determined by administration of Albunex [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(5): 514-518.
[4]	LIU Li-Ping. Clinical efficacy of urokinase in treatment of senium acute myocardial infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(5): 461-462.
[5]	CHEN Qian. Treatments of acute myocardial infarction with cardiogenic shock [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(5): 465-466.
[6]	ZHOU Hong-Qing, SUN Ming¹, HU Chan, LI Liu-Nan², LIU Zhi-Xiong³. Study of urokinase combined with magnesium sulfate in the treatment of early acute myocardial infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 1998, 3(3): 200-202.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 6

Recommended Articles

Metrics

Comments